

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(formerly known as China Pharmaceutical Group Limited 中國製藥集團有限公司)

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

CLARIFICATION ANNOUNCEMENT

This announcement is made by CSPC Pharmaceutical Group Limited 石藥集團有限公司 (formerly known as China Pharmaceutical Group Limited 中國製藥集團有限公司) (the “**Company**”) in response to some articles which appeared in certain news reports and internet websites on 2 April 2013 (the “**Articles**”) regarding a statement alleged to have been made by Mr. CHAK Kin Man (“**Mr. Chak**”), an executive director of the Company, at the Company’s results press conference held in Hong Kong on 2 April 2013 (the “**Press Conference**”).

The Company wishes to clarify on the following statement stated in the Articles following the Press Conference:

- Mr. Chak hopes that the Company’s dividend payout ratio for this year can be maintained at last year’s level of around 30%.

The Company would like to clarify that such statement is untrue and inaccurate because (i) Mr. Chak never made such statement and (ii) the Company’s dividend payout ratio for last year was not around 30%.

Shareholders and potential investors of the Company should not place any reliance on such statement and are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

CAI Dongchen

Chairman

Hong Kong, 2 April 2013

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin and Mr. WANG Zhenguo as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. HUO Zhenxing, Mr. QI Moujia, Mr. GUO Shichang, Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo and Mr. ZHANG Fawang as independent non-executive directors.